处方药属性:生长激素受严格监管,绝不可自行购买使用

身高管理 · 生长激素治疗深度解析

很多家长以为给孩子打上生长激素就完事了?大错特错!生长激素治疗, 不是 "打针就长高" 的简单过程, 而是一场持续数年、需要精细调整的马拉松。定期随访监测, 就是这场长跑的 "导航系统"。它确保孩子走在正确的生长轨道上, 并及时规避潜在风险。

随访的核心目标:安全与有效

1、看疗效:判断生长激素是否起效, 生长速度是否达标

2、调方案:根据生长情况调整用药剂量, 让治疗更精准

3、保安全:排查副作用, 确保血糖、甲状腺功能等正常

一张图看懂随访时间表与核心检查

处方药属性:生长激素受严格监管,绝不可自行购买使用

随访时间点

核心评估项目

目的与意义

启动治疗后3个月

身高、体重、IGF-1、甲状腺功能

基线评估:看身体对药物的初始反应和耐受性,调整起始剂量。

之后每3个月(第一年)

身高、体重、IGF-1、甲状腺功能、血糖

密集监测期:第一年是生长反应最关键的时期,需密切观察疗效和早期副作用。

第二年及以后(每6个月)

身高、体重、IGF-1、甲状腺功能、血糖、骨龄(每年1次)

长期管理期:评估长期疗效,监测骨龄进展(确保生长空间),持续保障安全。

处方药属性:生长激素受严格监管,绝不可自行购买使用

家长提前准备好这些, 让随访更高效

1、生长记录:在家定期测量的身高、体重数据

2、用药记录:用药剂量、是否漏打、打针后的反应

3、既往报告:之前的随访报告、检查结果, 方便医生评估

生长激素治疗的成功, 一半靠药物, 一半靠监测。

定期的专业随访, 不仅能确保孩子获得最大的生长获益, 更是保障长期用药安全的基石。请记住:没有监测的治疗, 是盲目的治疗。 做孩子成长路上负责任的 "领航员", 与医生携手, 为孩子铺就一条安全、有效的生长之路。

参考文献

  1. Allen, D. B., & Cuttler, L. (2013). Clinical practice. Short stature in childhood--challenges and choices. New England Journal of Medicine, 368(13), 1220–1228.
  2. Cohen, P., Rogol, A. D., Deal, C. L., Saenger, P., Reiter, E. O., Ross, J. L., ... & Wit, J. M. (2008). Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. The Journal of Clinical Endocrinology & Metabolism, 93(11), 4210-4217.
  3. Ranke, M. B., & Wit, J. M. (2018). Growth hormone - past, present and future. Nature Reviews Endocrinology, 14(5), 285-300.
  4. Bang, P., Bjerknes, R., Dahlgren, J., Dunkel, L., Gustafsson, J., Juul, A., ... & Norwegian Paediatric Endocrine Society. (2017). A comparison of different definitions of growth response for prediction of near adult height in growth hormone-treated children. Hormone Research in Paediatrics, 88(5), 319-328.
  5. Aisenberg, J., Aisenberg, G., & Aisenberg, E. (2002). Thyroid function in children with growth hormone (GH) deficiency during the first year of GH replacement therapy. Thyroid, 12(5), 451-456.
  6. Cutfield, W. S., Wilton, P., Bennmarker, H., Albertsson-Wikland, K., Chatelain, P., Ranke, M. B., & Price, D. A. (2000). Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. The Lancet, 355(9204), 610-613.
  7. Sävendahl, L., & Cooke, R. (2012). Long-term outcomes of growth hormone treatment in children born small for gestational age. Hormone Research in Paediatrics, 78(1), 1-3.
  8. Clayton, P. E., Cianfarani, S., Czernichow, P., Johannsson, G., Rapaport, R., & Rogol, A. (2007). Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. The Journal of Clinical Endocrinology & Metabolism, 92(3), 804-810.
  9. Carel, J. C., Ecosse, E., Landier, F., Meguellati-Hakkas, D., Kaguelidou, F., Rey, G., & Coste, J. (2012). Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. The Journal of Clinical Endocrinology & Metabolism, 97(2), 416-425.
← 返回文章列表